The Dangers of Electronic Cigarettes: A Call for Regulation

Aug.29.2022
The Dangers of Electronic Cigarettes: A Call for Regulation
Electronic cigarette use in Brazil raises concerns despite the country's effective tobacco control policies. Potential health risks exist.

In recent years, electronic cigarettes have gained a lot of attention online, causing many people to have doubts about their safety. Despite Brazil's ban on the production and sale of electronic cigarettes since 2009, their usage has significantly increased in recent years due to their easy availability on both websites and physical storefronts.


Brazil is known as a global model for tobacco control public policy. Policies implemented over the years from 1989 to 2019 have reduced tobacco consumption among those aged 18 and over by about 60%. Some of these policies prevented children and adolescents from accessing tobacco products, thus preventing them from smoking. However, unlike all efforts to reduce smoking through public health, a new smoking trend emerged: electronic cigarettes. This includes a nicotine release device, whose first prototype was created in Pennsylvania in 1963, but it was never commercialized. In 2003, electronic cigarettes were created in China and spread around the world a decade later after a major tobacco industry company acquired a patent for them.


Many young people are drawn to the various formats, designs, and flavors of electronic cigarettes, making up a significant proportion of e-cigarette users. Research shows that in Brazil, one in five young people aged 18-24 have already used e-cigarettes. Additionally, 80% of those who use e-cigarettes are between the ages of 18 and 34. However, studies indicate that apart from nicotine, the aerosol may also contain other irritants and toxic substances such as formaldehyde, acrolein, diethylene glycol, acetaldehyde, benzene, and low doses of carcinogens. Tests on cells, tissues, and small animals exposed to liquids from different brands of e-cigarettes indicate that they are toxic to neurological, respiratory, and cardiovascular cells and may have adverse effects and cause birth defects during critical stages of fetal development.


The safety of electronic nicotine delivery systems has not been scientifically proven. In fact, the amount of nicotine dispensed by different e-cigarette devices can vary greatly, exposing consumers to much higher doses of the substance than traditional cigarettes. Reports have linked multiple incidents of severe burns, dismemberment and even death to explosions of e-cigarette batteries, dependent on the device's position at the time of detonation.


Although there is a lack of research evaluating the long-term consequences of inhaled substances from these devices, it is well-known that in the short-term, they may trigger or exacerbate symptoms of previously existing conditions such as coughing, asthma, chronic obstructive pulmonary disease (COPD), and hypertension. Additionally, in 2019, a series of severe cases of lung illness related to the use of electronic cigarettes, known as EVALI, was reported in the United States. By 2020, these cases resulted in over 2,800 hospitalizations, with many in intensive care units, and 68 deaths. The majority of cases were in young people, with one patient requiring a lung transplant.


Although the tobacco industry has attempted to convey the idea that e-cigarettes can aid in quitting smoking, this is not a good strategy. E-cigarette use operates through the same mechanism as traditional cigarettes, providing the brain with a nicotine rush. This explains why over 80% of those who use e-cigarettes to quit smoking still rely on nicotine (and e-cigarettes) after a year of follow-up. Scientifically proven and effective behavioral and pharmacological therapies are available to help quit smoking.


Since 2009, the use of electronic cigarettes has been prohibited in Brazil and will continue to be banned. However, children and teenagers are still able to obtain them, and the rate of experimentation is increasing daily. It is time to acknowledge that electronic cigarettes are not just vaporizers and to implement monitoring and restrictions on their sales.


Statement:


This article is compiled from third-party information and is intended only for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS is unable to confirm the authenticity and accuracy of the content. The compilation of this article is only intended for industry discussion and research.


Due to limitations in our translation abilities, the translated article may not fully convey the original meaning. Please refer to the original article for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign related statements and positions.


The compilation of information is owned by the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
PMI Launches Mass Production of ZYN at $600M Aurora Manufacturing Hub
Philip Morris International (PMI), through its subsidiary Swedish Match, has started large-scale production at a 600,000-square-foot ZYN nicotine pouch facility in Aurora, Colorado. The $600 million investment makes the site one of three ZYN manufacturing plants in the United States and the company’s second U.S. facility after Owensboro, Kentucky.
PMI
Feb.21
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
German Environment Minister Backs Ban on Disposable E-Cigarettes, Citing Safety Risks
Germany’s Environment Minister Carsten Schneider has expressed clear support for banning disposable e-cigarettes, citing safety hazards, environmental damage, and waste management risks. While the ban has not yet been finalized, Germany’s parliament has instructed the government to examine the proposal. Several European countries, including Belgium, France, and the UK, have already implemented similar bans.
Dec.30 by 2FIRSTS.ai
Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law
Virginia asks Fourth Circuit to stay order blocking parts of its unauthorized-vape sales law
Virginia has asked the U.S. Court of Appeals for the Fourth Circuit to stay a district court order that blocks enforcement of certain provisions of a state law restricting the sale of unauthorized vaping products. The district court held the law was preempted to the extent it enforced federal requirements under the FDCA and the Tobacco Control Act.
Jan.21 by 2FIRSTS.ai
Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas Lawmakers Hear SB 355 to License E-Cigarette Makers, Citing Illicit China Imports
Kansas lawmakers held a Senate committee hearing on Senate Bill 355 on Jan. 27. The proposal would require e-cigarette manufacturers—potentially affecting distributors as well—to obtain a state license, expanding oversight beyond retailers.
Jan.28 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11